Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538055 | 0.88 | TAAR1 (0.56) | TAAR1FDFT1PPARGPPARAPNMT | |
| SCHEMBL13719088 | 0.87 | PPARG (0.59) | TAAR1FDFT1PPARGPPARAPNMT | |
| SCHEMBL17449706 | 0.84 | PPARG (0.43) | PPARGPPARAPNMTCETPCARM1 | |
| SCHEMBL8174800 | 0.83 | CETP (0.54) | TAAR1FDFT1PPARGPPARACETP | |
| SCHEMBL13719216 | 0.83 | KMO (0.48) | TAAR1FDFT1PPARGPPARAPNMT | |
| SCHEMBL13718717 | 0.82 | TAAR1 (0.60) | TAAR1CETPALDH1A1 | |
| SCHEMBL16316340 | 0.81 | ALDH1A1 (0.48) | FDFT1PPARGPPARAALDH1A1FAAH | |
| SCHEMBL13719546 | 0.81 | CARM1 (0.52) | PPARGPPARAALDH1A1CARM1PRMT6 | |
| SCHEMBL8172098 | 0.79 | FDFT1 (0.47) | TAAR1FDFT1PPARGPPARACETP | |
| SCHEMBL24726464 | 0.79 | TAAR1 (0.47) | TAAR1FDFT1PPARGPPARACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | TAAR1 2294/4885FDFT1 1139/4885PPARG 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.